1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 13,600 | 14,400 | 19.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.12. | Pharming Group N.V.: Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit | 230 | GlobeNewswire (Europe) | Leiden, the Netherlands, December 8, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the Oppenheimer Movers in Rare Disease Summit... ► Artikel lesen | |
| 06.11. | Pharming Group N.V. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 06.11. | Pharming GAAP EPS of $0.01 beats by $0.01, revenue of $97.3M beats by $4.46M | 5 | Seeking Alpha | ||
| 06.11. | Pharming Group N.V.: Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow | 442 | GlobeNewswire (Europe) | Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024RUCONEST® third quarter revenue increased by 29% to US$82.2 million, compared to third quarter 2024... ► Artikel lesen | |
| 30.10. | Pharming Group N.V.: Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London | 397 | GlobeNewswire (Europe) | Leiden, the Netherlands, October 30, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the Jefferies Global Healthcare... ► Artikel lesen | |
| PHARMING GROUP NV ADR Aktie jetzt für 0€ handeln | |||||
| 23.10. | Pharming Group N.V.: Pharming Group to report third quarter 2025 financial results and provide business update on November 6 | 356 | GlobeNewswire (Europe) | Leiden, the Netherlands, October 23, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the... ► Artikel lesen | |
| 22.10. | Pharming Group N.V. - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| 20.10. | Pharming Group N.V.: Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio | 5 | GlobeNewswire (USA) | ||
| 06.10. | Pharming Group N.V.: Pharming Group provides update on previously announced G&A expense reduction plan | 281 | GlobeNewswire (Europe) | Leiden, the Netherlands, October 6, 2025: Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation of an organizational restructuring to... ► Artikel lesen | |
| 03.10. | FDA accepts supplemental New Drug Application for Pharming's paediatric immunodeficiency therapy | 4 | PMLiVE | ||
| 02.10. | Pharming Group-Aktie steigt nach FDA-Zulassung für Leniolisib bei Kindern | 4 | Investing.com Deutsch | ||
| 02.10. | Pharming Group stock rises as FDA approves leniolisib for pediatric APDS | 2 | Investing.com | ||
| 01.10. | Pharming Group N.V. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 01.10. | Pharming shares jump 6% as FDA grants priority review for Joenja in children | 4 | Investing.com | ||
| 01.10. | FDA Accepts Pharming's SNDA For Leniolisib In Pediatric APDS; Priority Review Granted | 4 | RTTNews | ||
| 01.10. | Pharming Group N.V.: Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years | 565 | GlobeNewswire (Europe) | If approved, leniolisib will be first and only treatment indicated for children with activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS), a rare primary immunodeficiencyDecision based... ► Artikel lesen | |
| 10.09. | Pharming Group N.V. - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| 10.09. | Pharming Group N.V.: Pharming Group promoted to the Euronext AMX index | 327 | GlobeNewswire (Europe) | Leiden, the Netherlands, September 10, 2025: Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM; Nasdaq: PHAR) today announced that it has been promoted from the Euronext AScX® (Small... ► Artikel lesen | |
| 03.09. | Pharming Group N.V.: Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference | 463 | GlobeNewswire (Europe) | Leiden, the Netherlands, September 3, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the H.C. Wainwright 27th... ► Artikel lesen | |
| 02.09. | Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus | 25 | Zacks |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 8,110 | +2,71 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy | One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,541 | -1,66 % | PacBio Announces Third Quarter 2025 Financial Results | MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025Q3 2024Revenue$38.4... ► Artikel lesen | |
| ATAI BECKLEY | 3,361 | -0,74 % | Bioxyne Limited, Johnson & Johnson und Atai Life Sciences: MDMA-Forschung und ihre Bedeutung für die Traumatherapie | ||
| BIOMERIEUX | 108,70 | +0,09 % | BIOMERIEUX: bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health | ||
| BIO GREEN MED SOLUTION | 1,380 | 0,00 % | Bio Green Med Solution, Inc.: Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update | KUALA LUMPUR, Malaysia, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS, NASDAQ: BGMSP; "BGMS" or the "Company" (formerly Cyclacel Pharmaceuticals, Inc.)), a diversified... ► Artikel lesen | |
| GENUS | 29,400 | +0,68 % | Dividendenbekanntmachungen (06.11.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AIRTEL AFRICA PLC GB00BKDRYJ47 0,0216 GBP 0,0245 EUR ARMSTRONG WORLD INDUSTRIES INC US04247X1028 0,339 USD 0,2949 EUR ASHMORE GROUP... ► Artikel lesen | |
| ANAPTYSBIO | 42,200 | +0,48 % | GSK und AnaptysBio verklagen einander wegen angeblicher Lizenzverstöße | DJ GSK und AnaptysBio verklagen einander wegen angeblicher Lizenzverstöße
Von Elena Vardon
DOW JONES--Der Arzneimittelhersteller GSK und das US-Biotechunternehmen AnaptysBio haben einen Rechtsstreit... ► Artikel lesen | |
| ABIONYX PHARMA | 3,345 | -5,24 % | ABIONYX Pharma Carries Out a Capital Increase With Cancellation of Preferential Subscription Rights in Favor of Certain Categories of Persons, Amounting to Approximately €1.8m | Capital increase of approximately 1.8 million euros Subscription price: 3.10 euros Extension of financial visibility until the end of 2026
Regulatory News:
ABIONYX Pharma, (FR0012616852... ► Artikel lesen | |
| AKESO | 12,600 | -1,56 % | Akeso, Inc.: Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab | HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 0,640 | -0,78 % | XTL BIOPHARMACEUTICALS LTD - 6-K, Report of foreign issuer | ||
| MEIRAGTX | 6,750 | -1,46 % | MeiraGTx Reports Third Quarter 2025 Financial and Operational Results | Entered into broad strategic collaboration with Eli Lilly and Company ("Lilly") in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company's AAV-AIPL1 program for treatment... ► Artikel lesen | |
| MAAT PHARMA | 4,100 | -1,68 % | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): BUY | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
10.12.2025 / 11:25 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,049 | -2,00 % | Isofol Medical AB: European Patent Office intends to grant a new patent for Isofol's arfolitixorin | GOTHENBURG, Sweden, November 13 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the European Patent Office (EPO) has issued an Intention to Grant notice regarding a... ► Artikel lesen | |
| DIAGONAL BIO | 0,004 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 19.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 19.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 19.12.2025ISIN NameCA74349R1055 PROPHECY... ► Artikel lesen | |
| NURIX THERAPEUTICS | 18,520 | +2,83 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors | SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of... ► Artikel lesen |
Das Unternehmen PHARMING GROUP NV ADR kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 13,600 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMING GROUP NV ADR finden Sie auf Wallstreet Online.